SCHEMBL4480347

SCHEMBL4480347

CCOC(=O)c1ccc(-c2c3ccccc3nn2Cc2ccccc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 2/20 0.67
CYP19A1 P11511 4/20 0.55
SMN1; SMN2 Q16637 5/20 0.54
RECQL P46063 1/20 0.54
MAPK10 P53779 1/20 0.54
POLB P06746 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
MAPK1 P28482 1/20 0.50
MAPT P10636 2/20 0.49
PTGER4 P35408 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
BLM P54132 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4476606 0.84 MEN1 (0.51) F2RL3SMN1; SMN2RECQLMAPK10POLB
SCHEMBL4470865 0.84 PTGER4 (0.64) PTGER4
SCHEMBL363569 0.81 F2RL3 (1.00) F2RL3CYP19A1SMN1; SMN2RECQLMAPK10
SCHEMBL29403731 0.81 F2RL3 (1.00) F2RL3CYP19A1SMN1; SMN2RECQLMAPK10
SCHEMBL4494497 0.80 ALDH1A1 (0.53) CYP19A1SMN1; SMN2TDP1PTGER4ALDH1A1
SCHEMBL25966955 0.80 PTGER4 (0.64) F2RL3CYP19A1SMN1; SMN2RECQLMAPK10
SCHEMBL4487658 0.80 HDAC6 (0.56) PTGER4
SCHEMBL4481481 0.80 PTGER4 (0.55) MAPTPTGER4MEN1KMT2AGAA
SCHEMBL17322917 0.79 PTGER4 (0.60) F2RL3CYP19A1SMN1; SMN2RECQLMAPK10
SCHEMBL27669290 0.76 L3MBTL1 (0.56) SMN1; SMN2MAPTPTGER4ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100516049-C Antiangiogenic agent N2Synthesis of- (substituted arylmethyl) -3- (substituted phenyl) indazoles YUNG SHIN PHARM IND CO LTD (CN) 2009-07-22 CN disclosed
US-7514465-B2 Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2009-04-07 US disclosed
CN-1962640-A Novel anti-angiogenic drug N2Synthesis of- (substituted arylmethyl) -3- (substituted phenyl) indazoles YUNG SHIN PHARM IND CO LTD (CN) 2007-05-16 CN disclosed
EP-1659115-A1 Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents Yung Shin Pharm. Ind. Co., Ltd. (TW) 2006-05-24 EP disclosed
US-20060106032-A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents YUNG SHIN PHARM. IND. CO., LTD. (TW) 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106032-A1 Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents FLT4, FLT1, KDR F2RL3 611/4885CYP19A1 1664/4885SMN1; SMN2 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.